Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors.

Abstract

Purpose Hand-foot syndrome is a common dose limiting toxicity of vascular endothelial growth factor receptor tyrosine kinase inhibitors used for treatment of patients with metastatic renal cell carcinoma. The effect of treatment dose reductions, in the context of hand-foot syndrome, on survival outcomes is reported. Methods This was a retrospective case series of patients receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors from 1 January 2004 to 31 October 2013. The main outcomes were progression-free and overall survival in these patients experiencing hand-foot syndrome and undergoing treatment dose reductions. Univariate and multivariate analyses were conducted utilizing Kaplan-Meier method and COX Proportional Hazard model with landmark analyses at 2 months. Results Of the 120 patients evaluated, treatment dose reductions for any reason were required in 68 (56.7%) patients. The most common reasons for treatment dose reductions were mucositis, hand-foot syndrome, and fatigue. The median progression-free survival and overall survival were significantly longer in patients with hand-foot syndrome with or without treatment dose reductions as compared to those without hand-foot syndrome. Conclusions An improvement in survival outcomes was observed in metastatic renal cell carcinoma patients with treatment-associated hand-foot syndrome despite treatment dose reductions. These data need validation in a larger cohort to confirm the hypothesis that treatment dose reductions in the setting of hand-foot syndrome do not negatively impatient survival.

• Authors: Erin B Bailey, Joseph Merriman, Benjamin Maughan, Austin Poole, Srinivas K Tantravahi, Archana M Agarwal, Julia A Batten, Shiven B Patel, Sumanta K Pal, David D Stenehjem, Neeraj Agarwal
• Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (J Oncol Pharm Pract) Vol. 24 Issue 3 Pg. 190-197 (Apr 2018) ISSN: 1477-092X [Electronic] England
• PMID: 28436250 (Publication Type: Journal Article)

Chemical References

• Protein Kinase Inhibitors
• Vascular Endothelial Growth Factor A

Topics

• Adult
• Aged
• Aged, 80 and over
• Carcinoma, Renal Cell (drug therapy, mortality)
• Disease-Free Survival
• Dose-Response Relationship, Drug
• Female
• Follow-Up Studies
• Hand-Foot Syndrome (mortality)
• Humans
• Kidney Neoplasms (drug therapy, mortality)
• Male
• Middle Aged
• Protein Kinase Inhibitors (administration & dosage, adverse effects)
• Retrospective Studies
• Survival Rate (trends)
• Treatment Outcome
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)